biologics license application

https://www.biospace.com/celltrion-usa-announces-submission-of-the-biologics-license-application-bla-of-novel-subcutaneous-formulation-of-ct-p13-to-u-s-food-and-drug-administration Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous... Dec 23, 2022 - Celltrion USA announced the submission of a Biologics License Application under the 351 pathway of the Public Health Service Act for lead product candidate,... biologics license application of the https://www.fiercebiotech.com/biotech/merck-announces-fda-acceptance-of-biologics-license-application-for-bezlotoxumab-an Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an... Jan 27, 2016 - KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug... biologics license application merck announces fda acceptance https://www.biospace.com/harbour-biomed-announces-resubmission-of-biologics-license-application-for-batoclimab-to-nmpa-for-treatment-of-generalized-myasthenia-gravis Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for... Jun 26, 2024 - Harbour BioMed (the "Company"; HKEX: 02142) announces that it has resubmitted the Biologics License Application (BLA) of batoclimab (HBM9161) to the National... biologics license application https://www.newsfilecorp.com/release/203028 FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat... Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that... biologics license application https://investingnews.com/tag/biologics-license-application biologics license application | INN biologics license application inn https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_submission_of_biologics_license_application_to_the_fda_for_investigational_meningococcal_b_vaccine Pfizer Announces Submission of Biologics License Application to the FDA for Investigational... biologics license application https://www.biospace.com/u-s-fda-accepts-biologics-license-application-for-gc-biopharma-s-gc5107b-immune-globulin-intravenous-human-10-percent-liquid U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin... Jul 31, 2023 - GC Biopharma, a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, announced that the U.S. Food and Drug Administration has... u s fda biologics license application https://www.biospace.com/neurotech-pharmaceuticals-inc-receives-priority-review-of-biologics-license-application-bla-for-nt-501-revakinagene-taroretcel-as-a-treatment-for-macular-telangiectasia-type-2-mactel Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for... Jun 20, 2024 - Neurotech Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA), has determined that the Biologic License Application (BLA) for... biologics license application priority review https://www.biospace.com/press-releases/merck-announces-fda-acceptance-of-biologics-license-application-for-clesrovimab-an-investigational-long-acting-monoclonal-antibody-designed-to-protect-infants-from-rsv-disease-during-their-first-rsv-season Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational... biologics license application https://melanoma.org/news-press/iovance-biotherapeutics-initiates-biologics-license-application-bla-submission-for-lifileucel-in-advanced-melanoma/ Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in... biologics license application iovance biotherapeutics initiates https://www.roche.com/media/releases/med-cor-2019-02-05 Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant... Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy... biologics license application https://www.businesswire.com/news/home/20221006005843/en/Hugel-Aesthetics-Resubmits-Biologics-License-Application-for-LetibotulinumtoxinA-for-Injection-for-Glabellar-Lines-to-the-FDA Hugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for... Hugel America, Inc. (Hugel Aesthetics) announced today that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administrati... biologics license application hugel aesthetics letibotulinumtoxina injection https://www.prnewswire.com/news-releases/secure-transfusion-solutions-granted-its-first-biologics-license-application-approval-301712637.html Secure Transfusion Solutions Granted its First Biologics License Application Approval /PRNewswire/ -- Secure Transfusion Solutions (STS), a private life sciences company pioneering innovative methods to overcome the nation's growing blood and... biologics license application secure transfusion solutions granted https://www.prnewswire.com/news-releases/fda-accepts-biologics-license-application-for-subcutaneous-formulation-of-herceptin-300679077.html FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License... biologics license application fda accepts subcutaneous formulation https://www.globenewswire.com/fr/news-release/2026/02/19/3240927/0/en/garetosmab-biologics-license-application-accepted-for-fda-priority-review-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop.html Garetosmab Biologics License Application Accepted for FDA FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues,... biologics license application garetosmab accepted fda https://www.merck.com/news/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o/ FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants... May 11, 2026 - Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority... biologics license application priority review fda accepts supplemental https://www.businesswire.com/news/home/20260331950583/en/Scholar-Rock-Resubmits-Biologics-License-Application-BLA-to-FDA-for-Apitegromab-for-Treatment-of-Children-and-Adults-with-Spinal-Muscular-Atrophy-SMA Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of... Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) an... biologics license application https://www.amgen.com/newsroom/press-releases/2010/07/fda-grants-priority-review-designation-to-denosumab-biologics-license-application-for-the-reduction-of-skeletal-related-events-in-advanced-cancer-patients FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction... biologics license application https://www.roche.com/media/releases/med-cor-2019-01-17 FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy... Basel, 17 January 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's... biologics license application https://www.gilead.com/news/news-details/2021/gilead-submits-biologics-license-application-to-us-food-and-drug-administration-for-bulevirtide-an-investigational-treatment-for-people-living-with-chronic-hepatitis-delta Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide,... Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide an Investigational Treatment for People Living With Chronic... food and drug administration https://www.prnewswire.com/news-releases/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-of-adults-with-active-psoriatic-arthritis-302714083.html Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for... /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its...

Robuta